Drug
Asciminib Single Agent
Asciminib Single Agent: highest development phase Post-Market, developed by Novartis. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Asciminib single agent NCT04877522 | Post-Market | Chronic Myelogenous Leukemia |
| Asciminib single agent NCT07354074 | Phase 2 | Chronic Myelogenous Leukemia |
Latest
No recent events.
Follow Asciminib Single Agent on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.